88 search results for: Clinical Management
FeNO as a Biomarker for Type 2 Asthma
Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.
IgE as a Biomarker for Type 2 Asthma
Dr. Jonathan Corren describes the diagnostic, predictive, and prognostic role of IgE as a biomarker of type 2 inflammation in asthma.
Eosinophils as a Biomarker for Type 2 Asthma
Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.
ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?
Join Klaus Rabe, MD, PhD, FERS; Celeste Porsberg, MD, PhD; and Mario Castro, MD, MPH, for a symposium on airway remodeling in severe asthma patients.
ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation
Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses how early dupilumab intervention in pediatric atopic dermatitis may alter the atopic march, reducing the risk of developing atopic comorbidities as well as nonatopic comorbidities such as infections and psychosomatic issues.
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.
ERS-ISIAN 2025 | Disease Control in CRSwNP
Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.
